⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 31, 2026American Journal of Clinical DermatologyOpen Access

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies

Maryanne Senna Jennifer Soung Ignasi Gimeno Figueras Brett King Misaki Kinoshita-Ise Sameh Hanna Wenyu Wu Dalia Wajsbrot Deborah Woodworth Robert Wolk Alanna Chaudhry Alexandre Lejeune Helen Tran

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata.
Conducted Phase 2b/3 and Phase 3 clinical studies
Monitored participants for three years
Assessed treatment efficacy and safety outcomes
Ritlecitinib showed a significant improvement in hair regrowth over three years
Adverse effects were manageable, indicating good safety profile
Results suggest sustained benefit in hair regrowth for individuals with alopecia areata

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Clinical studies demonstrate long-term efficacy and safety of ritlecitinib in treating alopecia areata, indicating promise for affected individuals.

Abstract

Nct03732807, Nct04006457, Nct04517864, Nct02974868.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Senna et al. (2026) studied this question.

synapsesocial.com/papers/69cf5e2e5a333a821460c576 https://doi.org/10.1007/s40257-026-01029-y

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata2024 · 6 citations
2Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the <scp>ALLEGRO</scp> ‐2b/3 and <scp>ALLEGRO</scp> ‐ <scp>LT</scp> Clinical Studies for Alopecia AreataEarly-Phase Clinical Trial · 2026 · 2 citations
3Efficacy and safety of ritlecitinib, an oral <scp>JAK3</scp>/<scp>TEC</scp> family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis2024 · 12 citations
4Real-World Efficacy of Ritlecitinib in Adolescent Patients With Alopecia Areata: A 36 Week Monocentric Real-Life Observational StudyHuman Clinical Trial · 2026 · 2 citations
5723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study2024 · 1 citations

More related papers

Ritlecitinib for the treatment of severe alopecia areata: real-world experience from a UK tertiary centre2026
Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From <scp>ALLEGRO</scp>‐2b/32025
Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study2026

More from American Journal of Clinical Dermatology

Rosacea in Patients with Skin of Color: Diagnosis and ManagementMon,
Cutaneous Aging in Skin of Color: A Narrative ReviewFri,